(R)-6-bromo-2-(2-(2-methylpyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one | 1131222-67-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: (R)-6-bromo-2-(2-(2-methylpyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one
• 英文别名: (R)-6-Bromo-2-[2-(2-methylpyrrolidin-1-yl)ethyl]-3,4-dihydroisoquinolin-1(2H)-one；6-bromo-2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]-3,4-dihydroisoquinolin-1-one
• CAS: 1131222-67-7
• 化学式: C₁₆H₂₁BrN₂O
• 分子量: 337.26
• InChiKey: ZTWUIRCUFULZTI-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-6-bromo-2-(2-(2-methylpyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one 在 氯化亚砜 、 二氯双(三邻甲苯膦)合钯(II) 、 水 、 potassium carbonate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 5.5h， 生成 N-methyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide hydrochloride
  参考文献：
  名称：

  2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one Derivatives as Potent and Selective Histamine-3 Receptor Antagonists

  摘要：

  On the basis of the previously reported benzimidazole 1,3'-bipyrrolidine benzamides (1), a new class of 2-(pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives (3-50) were synthesized and evaluated as potent H-3 receptor antagonists. In particular, compound 39 exhibited potent in vitro binding and functional activities at the H-3 receptor, good selectivities against other neurotransmitter receptors and ion channels, acceptable pharmacokinetic properties, and a favorable in vivo profile.

  DOI：

  10.1021/jm300011d
• 作为产物：
  描述：

  2-allyl-6-bromo-3,4-dihydroisoquinolin-1-one 在 sodium periodate 、 sodium cyanoborohydride 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 8.17h， 生成 (R)-6-bromo-2-(2-(2-methylpyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one
  参考文献：
  名称：

  2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one Derivatives as Potent and Selective Histamine-3 Receptor Antagonists

  摘要：

  On the basis of the previously reported benzimidazole 1,3'-bipyrrolidine benzamides (1), a new class of 2-(pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives (3-50) were synthesized and evaluated as potent H-3 receptor antagonists. In particular, compound 39 exhibited potent in vitro binding and functional activities at the H-3 receptor, good selectivities against other neurotransmitter receptors and ion channels, acceptable pharmacokinetic properties, and a favorable in vivo profile.

  DOI：

  10.1021/jm300011d

文献信息

• ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS
  申请人：Zhou Dahui

  公开号：US20090069300A1

  公开（公告）日：2009-03-12

  The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.

  本发明提供了一种公式I的化合物及其用于治疗与组胺-3受体相关或受其影响的中枢神经系统疾病的应用。
• [EN] ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS<br/>[FR] DÉRIVÉS D'ISOQUINOLINYLE ET D'ISOINDOLINYLE CONVENANT COMME ANTAGONISTES DE L'HISTAMINE-3
  申请人：WYETH CORP

  公开号：WO2009036144A1

  公开（公告）日：2009-03-19

  The present invention provides a compound of formula (I) and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.
• 2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(<i>2H</i>)-one Derivatives as Potent and Selective Histamine-3 Receptor Antagonists
  作者：Dahui Zhou、Jonathan L. Gross、Adedayo B. Adedoyin、Suzan B. Aschmies、Julie Brennan、Mark Bowlby、Li Di、Katie Kubek、Brian J. Platt、Zheng Wang、Guoming Zhang、Nicholas Brandon、Thomas A. Comery、Albert J. Robichaud

  DOI：10.1021/jm300011d

  日期：2012.3.8

  On the basis of the previously reported benzimidazole 1,3'-bipyrrolidine benzamides (1), a new class of 2-(pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives (3-50) were synthesized and evaluated as potent H-3 receptor antagonists. In particular, compound 39 exhibited potent in vitro binding and functional activities at the H-3 receptor, good selectivities against other neurotransmitter receptors and ion channels, acceptable pharmacokinetic properties, and a favorable in vivo profile.